Zervimesine (CT1812) Treatment Benefits Patients with Lower Baseline Plasma p‐tau217 Across the Mild‐to‐Moderate AD Spectrum

Abstract

Background: Zervimesine (CT1812) is an experimental oral, small‐molecule drug candidate in development for Alzheimer’s disease (AD) and dementia with Lewy bodies. Zervimesine is designed to protect neuronal synapses by preventing the binding of amyloid beta (Aβ) oligomers.

The paper